Search: onr:"swepub:oai:DiVA.org:uu-441708" >
Bortezomib-Based In...
-
Cornell, Robert F.AbbVie, N Chicago, IL USA
(author)
Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
Elsevier,2021
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-441708
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441708URI
-
https://doi.org/10.1016/j.jtct.2020.11.018DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:146292024URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
The benefits of pre-transplant induction chemotherapy in light chain (AL) amyloidosis, a low burden plasma cell (PC) neoplasm associated with multiorgan dysfunction, is debatable, although with the availability of bortezomib, this approach is being increasingly pursued. We analyzed the outcomes of AL amyloidosis patients undergoing autologous hematopoietic cell transplant between 2014 and 2018 that were reported to the Center for International Blood and Marrow Transplant Research database. Of 440 patients, 294 received bortezomib-based induction, and 146 received no induction. Patients receiving induction had greater PC burden compared to no induction (PC 10% or more, 39% versus 11%; P < .01). At 2 years, the induction group compared to no induction had lower relapse/progression: 13% (9% to 18%) versus 23% (16% to 32%) (P = .02); better progression-free survival (PFS): 82% (77% to 87%) versus 69% (61% to 77%) (P < .01); and similar overall survival (OS): 92% (88% to 95%) versus 89% (84% to 94%) (P = .22), findings that were confirmed on multivariate analysis. A subset analysis limited to patientswith <10% PC also showed superior relapse/progression (hazard ratio [HR],.43; 95% confidence interval [CI],.24 to.78; P < .01) and PFS (HR,.43; 95% CI,.26 to .72; P < .01) for induction compared to no induction. Thus, we conclude that pre-transplant bortezomib-based induction was associated with improved relapse/progression and PFS in AL amyloidosis. Longer survival follow-up is warranted, as OS was excellent in both cohorts at 2 years.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Fraser, RaphaelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA
(author)
-
Costa, LucianoUniv Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
(author)
-
Goodman, StaceyVanderbilt Univ, Med Ctr, Nashville, TN USA
(author)
-
Estrada-Merly, NoelMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
Lee, CindyRoyal Adelaide Hosp, Adelaide, SA, Australia
(author)
-
Hildebrandt, GerhardUniv Kentucky, Markey Canc Ctr, Lexington, KY USA
(author)
-
Gergis, UsamaThomas Jefferson Univ, Dept Med Oncol, Div Hematol Malignancies, Philadelphia, PA 19107 USA
(author)
-
Farhadfar, NoshaUniv Florida, Coll Med, Div Hematol Oncol, Gainesville, FL USA
(author)
-
Freytes, César O.Texas Transplant Inst, San Antonio, TX USA
(author)
-
Kamble, Rammurti T.Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
(author)
-
Krem, MaxwellUniv Kentucky, Markey Canc Ctr, Lexington, KY USA
(author)
-
Kyle, Robert A.Mayo Clin Rochester, Rochester, MN USA
(author)
-
Lazarus, Hillard M.Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Cleveland, OH 44106 USA
(author)
-
Marks, David I.Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England
(author)
-
Meehan, KennethDartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
(author)
-
Patel, Sagar S.Univ Utah, Blood & Marrow Transplant Program, Salt Lake City, UT USA
(author)
-
Ramanathan, MuthalaguUMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA
(author)
-
Olsson, Richard F.Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden(Swepub:uu)riols677
(author)
-
Wagner, John L.Thomas Jefferson Univ, Dept Med Oncol, Philadelphia, PA 19107 USA
(author)
-
Kumar, ShajiMayo Clin Rochester, Rochester, MN USA
(author)
-
Qazilbash, Muzaffar H.MD Anderson Canc Ctr, Houston, TX USA
(author)
-
Shah, NinahUniv Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA
(author)
-
Hari, ParameswaranMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
D'Souza, AnitaMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
(author)
-
AbbVie, N Chicago, IL USAMed Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Inst Hlth & Equ, Div Biostat, Milwaukee, WI 53226 USA
(creator_code:org_t)
Related titles
-
In:Transplantation and Cellular Therapy: Elsevier27:3, s. 264.e1-264.e72666-63752666-6367
Internet link
Find in a library
To the university's database
- By the author/editor
-
Cornell, Robert ...
-
Fraser, Raphael
-
Costa, Luciano
-
Goodman, Stacey
-
Estrada-Merly, N ...
-
Lee, Cindy
-
show more...
-
Hildebrandt, Ger ...
-
Gergis, Usama
-
Farhadfar, Nosha
-
Freytes, César O ...
-
Kamble, Rammurti ...
-
Krem, Maxwell
-
Kyle, Robert A.
-
Lazarus, Hillard ...
-
Marks, David I.
-
Meehan, Kenneth
-
Patel, Sagar S.
-
Ramanathan, Muth ...
-
Olsson, Richard ...
-
Wagner, John L.
-
Kumar, Shaji
-
Qazilbash, Muzaf ...
-
Shah, Ninah
-
Hari, Parameswar ...
-
D'Souza, Anita
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Transplantation ...
- By the university
-
Uppsala University
-
Karolinska Institutet